JPWO2019143948A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019143948A5 JPWO2019143948A5 JP2020539806A JP2020539806A JPWO2019143948A5 JP WO2019143948 A5 JPWO2019143948 A5 JP WO2019143948A5 JP 2020539806 A JP2020539806 A JP 2020539806A JP 2020539806 A JP2020539806 A JP 2020539806A JP WO2019143948 A5 JPWO2019143948 A5 JP WO2019143948A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- nanoparticles
- sequence represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023154196A JP2023179521A (ja) | 2018-01-18 | 2023-09-21 | 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618908P | 2018-01-18 | 2018-01-18 | |
| US62/618,908 | 2018-01-18 | ||
| PCT/US2019/014209 WO2019143948A1 (en) | 2018-01-18 | 2019-01-18 | Altering inflammatory states of immune cells in vivo by modulating cellular activation states |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023154196A Division JP2023179521A (ja) | 2018-01-18 | 2023-09-21 | 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512056A JP2021512056A (ja) | 2021-05-13 |
| JPWO2019143948A5 true JPWO2019143948A5 (ko) | 2022-02-24 |
| JP7355742B2 JP7355742B2 (ja) | 2023-10-03 |
Family
ID=67302460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539806A Active JP7355742B2 (ja) | 2018-01-18 | 2019-01-18 | 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること |
| JP2023154196A Pending JP2023179521A (ja) | 2018-01-18 | 2023-09-21 | 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023154196A Pending JP2023179521A (ja) | 2018-01-18 | 2023-09-21 | 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210046156A1 (ko) |
| EP (1) | EP3740198A4 (ko) |
| JP (2) | JP7355742B2 (ko) |
| KR (1) | KR20200109325A (ko) |
| CN (1) | CN111629715A (ko) |
| AU (2) | AU2019210188B2 (ko) |
| CA (1) | CA3088122A1 (ko) |
| IL (1) | IL276122A (ko) |
| WO (1) | WO2019143948A1 (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| CA3049244A1 (en) | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
| WO2019006371A1 (en) * | 2017-06-30 | 2019-01-03 | City Of Hope | COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY |
| CA3162629A1 (en) * | 2019-12-31 | 2021-07-08 | Matthias Stephan | Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites |
| EP4215214A4 (en) * | 2020-09-16 | 2024-07-03 | Univ Osaka | CANCER THERAPEUTICS, IMMUNOSTIMULANT AND SCREENING METHODS FOR AN ANTICANCER SUBSTANCE |
| CN114621929B (zh) * | 2021-12-21 | 2023-05-30 | 河南省肿瘤医院 | 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用 |
| CN117919450A (zh) * | 2023-12-31 | 2024-04-26 | 上海市东方医院（同济大学附属东方医院） | 一种以吞噬细胞为载体的环状rna药物及其制备和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242253B1 (en) * | 1997-10-09 | 2001-06-05 | Regents Of The University Of California | IkB kinase, subunits thereof, and methods of using same |
| CA2325354A1 (en) * | 1998-04-07 | 1999-10-14 | The Sir Mortimer B. Davis - Jewish General Hospital | Highly active forms of interferon regulatory factor proteins |
| EP1465996B1 (en) * | 2001-12-21 | 2008-11-05 | Laboratoires Serono SA | Raf/ras binding compounds |
| WO2006079176A1 (en) * | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| US20090136917A1 (en) * | 2007-10-25 | 2009-05-28 | Szalay Aladar A | Systems and methods for viral therapy |
| WO2012093258A2 (en) * | 2011-01-05 | 2012-07-12 | Imperial Innovations Limited | Treatment and screening |
| GB201302427D0 (en) * | 2013-02-12 | 2013-03-27 | Midatech Ltd | Nanoparticle delivery compositions |
| US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| WO2018081459A1 (en) | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| CA3049244A1 (en) * | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
-
2019
- 2019-01-18 CN CN201980009095.4A patent/CN111629715A/zh active Pending
- 2019-01-18 CA CA3088122A patent/CA3088122A1/en active Pending
- 2019-01-18 KR KR1020207022164A patent/KR20200109325A/ko not_active Application Discontinuation
- 2019-01-18 EP EP19740957.6A patent/EP3740198A4/en active Pending
- 2019-01-18 US US16/963,119 patent/US20210046156A1/en active Pending
- 2019-01-18 AU AU2019210188A patent/AU2019210188B2/en active Active
- 2019-01-18 WO PCT/US2019/014209 patent/WO2019143948A1/en unknown
- 2019-01-18 JP JP2020539806A patent/JP7355742B2/ja active Active
-
2020
- 2020-07-16 IL IL276122A patent/IL276122A/en unknown
-
2023
- 2023-09-21 JP JP2023154196A patent/JP2023179521A/ja active Pending
-
2024
- 2024-05-21 AU AU2024203377A patent/AU2024203377A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019143948A4 (en) | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | |
| Vostakolaei et al. | Hsp70 in cancer: A double agent in the battle between survival and death | |
| Müller et al. | Bidirectional crosstalk between cancer stem cells and immune cell subsets | |
| Thaci et al. | Significance of interleukin-13 receptor alpha 2–targeted glioblastoma therapy | |
| Kim et al. | The molecular mechanism for nuclear transport and its application | |
| JP2018528774A5 (ko) | ||
| Jamali et al. | Highly efficient and selective CAR-gene transfer using CD4-and CD8-targeted lentiviral vectors | |
| Bernardes et al. | Engineering of bacterial strains and their products for cancer therapy | |
| Sharma et al. | Receptor-targeted glial brain tumor therapies | |
| JPWO2019143948A5 (ko) | ||
| US20200407418A1 (en) | Cell-Mediated Exosome Delivery | |
| Suwan et al. | Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer | |
| Xie et al. | Circular RNA: a promising new star of vaccine | |
| JPWO2019213517A5 (ko) | ||
| Vadevoo et al. | IL4 Receptor–targeted proapoptotic peptide blocks tumor growth and metastasis by enhancing antitumor immunity | |
| CN111592601A (zh) | 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用 | |
| Wu et al. | Distinct Role of CD11b+ Ly6G− Ly6C− Myeloid-Derived Cells on the Progression of the Primary Tumor and Therapy-Associated Recurrent Brain Tumor | |
| Chen et al. | Clinical investigations of CAR-T cell therapy for solid tumors | |
| CN111925448A (zh) | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 | |
| Tsuchida et al. | Targeted nonviral delivery of genome editors in vivo | |
| Clayton et al. | Immunoregulatory potential of exosomes derived from cancer stem cells | |
| Kitzberger et al. | Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice | |
| CA2890595C (en) | Cytolytic fusion proteins for inducing apoptosis | |
| Nemudraya et al. | Tumor-specific peptide, selected from a phage peptide library, enhances antitumor activity of lactaptin | |
| Liu et al. | Tumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma |